Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

te arai biofarma limited - eplerenone 50mg - film coated tablet - 50 mg - active: eplerenone 50mg excipient: croscarmellose sodium hypromellose microcrystalline cellulose (type 102) lactose monohydrate magnesium stearate microcrystalline cellulose opadry white oy-l-28900 purified talc purified water sodium laurilsulfate - to reduce the risk of cardiovascular death in combination with standard therapy in patients who have evidence of heart failure and left ventricular impairment within 3 to 14 days of an acute myocardial infarction.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

wasatch product development - menthol (unii: l7t10eip3a) (menthol - unii:l7t10eip3a), methyl salicylate (unii: lav5u5022y) (salicylic acid - unii:o414pz4lpz) - uses provides warming, penetrating pain relief for sore muscles and joints may also provide temporary relief of minor aches and pains associated with backache, strains and bruises if condition worsens, or if symptoms persist for more than 7 days or clear up and occur again within a few days, discontinue use of product and consult a physician.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - methylphenidate hydrochloride, quantity: 36 mg - tablet, modified release - excipient ingredients: triethyl citrate; methacrylic acid copolymer; lactose monohydrate; hypromellose; colloidal anhydrous silica; purified talc; magnesium stearate; fumaric acid; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; titanium dioxide; polyvinyl alcohol; macrogol 3350 - te-methylphenidate xr is indicated for the treatment of attention deficit hyperactivity disorder (adhd). treatment should be commenced by a specialist.,a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years.,need for comprehensive treatment programme te-methylphenidate xr is indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. appropriate educational placement is essential and psychosocial intervention is often helpful. when remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician?s assessment of the chronicity and severity of the patient?s symptoms.,long term use the effectiveness of methylphenidate hydrochloride extended release tablets for long-term use has not been systematically evaluated in controlled trials. therefore the physician who elects to use te-methylphenidate xr for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - methylphenidate hydrochloride, quantity: 27 mg - tablet, modified release - excipient ingredients: colloidal anhydrous silica; lactose monohydrate; methacrylic acid copolymer; purified talc; fumaric acid; magnesium stearate; triethyl citrate; hypromellose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; titanium dioxide; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - te-methylphenidate xr is indicated for the treatment of attention deficit hyperactivity disorder (adhd). treatment should be commenced by a specialist.,a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years.,need for comprehensive treatment programme te-methylphenidate xr is indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. appropriate educational placement is essential and psychosocial intervention is often helpful. when remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician?s assessment of the chronicity and severity of the patient?s symptoms.,long term use the effectiveness of methylphenidate hydrochloride extended release tablets for long-term use has not been systematically evaluated in controlled trials. therefore the physician who elects to use te-methylphenidate xr for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - methylphenidate hydrochloride, quantity: 54 mg - tablet, modified release - excipient ingredients: purified talc; colloidal anhydrous silica; methacrylic acid copolymer; fumaric acid; magnesium stearate; lactose monohydrate; triethyl citrate; hypromellose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; titanium dioxide; iron oxide red; polyvinyl alcohol; macrogol 3350 - te-methylphenidate xr is indicated for the treatment of attention deficit hyperactivity disorder (adhd). treatment should be commenced by a specialist.,a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years.,need for comprehensive treatment programme te-methylphenidate xr is indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. appropriate educational placement is essential and psychosocial intervention is often helpful. when remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician?s assessment of the chronicity and severity of the patient?s symptoms.,long term use the effectiveness of methylphenidate hydrochloride extended release tablets for long-term use has not been systematically evaluated in controlled trials. therefore the physician who elects to use te-methylphenidate xr for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - methylphenidate hydrochloride, quantity: 18 mg - tablet, modified release - excipient ingredients: colloidal anhydrous silica; magnesium stearate; fumaric acid; lactose monohydrate; triethyl citrate; purified talc; methacrylic acid copolymer; hypromellose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; titanium dioxide; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - te-methylphenidate xr is indicated for the treatment of attention deficit hyperactivity disorder (adhd). treatment should be commenced by a specialist.,a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years.,need for comprehensive treatment programme te-methylphenidate xr is indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. appropriate educational placement is essential and psychosocial intervention is often helpful. when remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician?s assessment of the chronicity and severity of the patient?s symptoms.,long term use the effectiveness of methylphenidate hydrochloride extended release tablets for long-term use has not been systematically evaluated in controlled trials. therefore the physician who elects to use te-methylphenidate xr for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

te arai biofarma limited - dimethyl fumarate 120mg - modified release capsule - 120 mg - active: dimethyl fumarate 120mg excipient: colloidal silicon dioxide crospovidone sheffcoat clear asa 5x00294 sheffcoat white ent tec 5x00273 capsugel white op/green op c162 magnesium stearate microcrystalline cellulose povidone - indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

te arai biofarma limited - zonisamide 100mg - capsule - 100 mg - active: zonisamide 100mg excipient: gelatin hydrogenated vegetable oil microcrystalline cellulose polyethylene glycol hydrogenated castor oil ponceau 4r purified water quinoline yellow titanium dioxide - monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy. adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

te arai biofarma limited - zonisamide 25mg - capsule - 25 mg - active: zonisamide 25mg excipient: gelatin hydrogenated vegetable oil microcrystalline cellulose polyethylene glycol hydrogenated castor oil purified water titanium dioxide - monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy. adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

te arai biofarma limited - zonisamide 50mg - capsule - 50 mg - active: zonisamide 50mg excipient: gelatin hydrogenated vegetable oil iron oxide black microcrystalline cellulose polyethylene glycol hydrogenated castor oil purified water titanium dioxide - monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy. adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above.